GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Deferred Tax

KalVista Pharmaceuticals (STU:4XC1) Deferred Tax : €0.00 Mil (TTM As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

KalVista Pharmaceuticals's change in deferred tax for the three months ended in Jan. 2024 was €0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jan. 2024 was €0.00 Mil.

KalVista Pharmaceuticals Deferred Tax Historical Data

The historical data trend for KalVista Pharmaceuticals's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Deferred Tax Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

KalVista Pharmaceuticals Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals Deferred Tax Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Deferred Tax
Comparable Companies
AVTE FUSN PGEN QURE RPHM JANX THRD VIGL AURA MGTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KALV:USA 4XC1:Germany
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
Website
https://www.kalvista.com
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines